Leerink Swann Upgrades Incyte (INCY) to Outperform; Ahead of the Curve: The JAK2 Inhibitor Storm in a Teacup
Tweet
Share
E-mailGet Alerts INCY Hot Sheet
Price: $120.16 -0.3%
Rating Summary:
17 Buy, 17 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
17 Buy, 17 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Leerink Swann upgraded Incyte (NASDAQ: INCY) from Market Perform
to Outperform.
Leerink analyst says, "We are upgrading INCY based on our view that over time it will shift the discussion from its role as a palliative agent to one as a truly disease modifying agent. We expect the disease modifying evidence (early signals from COMFORT-I & II then more pronounced versus historical controls over time) to drive both broader uptake in MF plus steady accumulation of patients. For our recent work on INCY, see our Heme-Onc Update and our ASH_Wrap-Up); we've recently also spoken with other MEDACorp hematologists which has helped crystallize our thinking. Our valuation range rises from hi teens to mid-$20s."
For more ratings news on Incyte click here and for the rating history of Incyte click here.
Shares of Incyte closed at $18.26 yesterday.
to Outperform.
Leerink analyst says, "We are upgrading INCY based on our view that over time it will shift the discussion from its role as a palliative agent to one as a truly disease modifying agent. We expect the disease modifying evidence (early signals from COMFORT-I & II then more pronounced versus historical controls over time) to drive both broader uptake in MF plus steady accumulation of patients. For our recent work on INCY, see our Heme-Onc Update and our ASH_Wrap-Up); we've recently also spoken with other MEDACorp hematologists which has helped crystallize our thinking. Our valuation range rises from hi teens to mid-$20s."
For more ratings news on Incyte click here and for the rating history of Incyte click here.
Shares of Incyte closed at $18.26 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Serve Robotics (SERV) to Buy
- JPMorgan Upgrades FOX Corp. (FOXA) to Overweight
- Kepler Cheuvreux Upgrades Swissquote Group Holding SA (SQN:SW) to Buy
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
